

Reinhard Hohlfeld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5411816/publications.pdf>

Version: 2024-02-01

68
papers

4,416
citations

117625

34
h-index

106344

65
g-index

71
all docs

71
docs citations

71
times ranked

6431
citing authors

#	ARTICLE	IF	CITATIONS
1	First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. <i>Journal of Neurology</i> , 2022, 269, 55-58.	3.6	54
2	Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal. <i>Multiple Sclerosis Journal</i> , 2022, 28, 16-28.	3.0	5
3	Twin study reveals non-heritable immune perturbations in multiple sclerosis. <i>Nature</i> , 2022, 603, 152-158.	27.8	45
4	Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair. <i>Neurotherapeutics</i> , 2022, 19, 774-784.	4.4	6
5	Toward identification of personalized immunological profiles in multiple sclerosis. <i>Science Advances</i> , 2022, 8, eabq4849.	10.3	1
6	Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA _A receptor encephalitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	16
7	Features of MOG required for recognition by patients with MOG antibody-associated disorders. <i>Brain</i> , 2021, 144, 2375-2389.	7.6	27
8	CD20 ⁺ T Cells as Pathogenic Players and Therapeutic Targets in MS. <i>Annals of Neurology</i> , 2021, 90, 722-724.	5.3	4
9	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	38
10	Multiple sclerosis meets systems immunology. <i>Lancet Neurology</i> , The, 2021, 20, 887-888.	10.2	1
11	Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS. <i>Acta Neuropathologica Communications</i> , 2020, 8, 207.	5.2	11
12	Immune signatures of prodromal multiple sclerosis in monozygotic twins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 21546-21556.	7.1	36
13	An expanded parenchymal CD8 ⁺ T cell clone in GABA _A receptor encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 239-244.	3.7	14
14	DNA methylation signatures of monozygotic twins clinically discordant for multiple sclerosis. <i>Nature Communications</i> , 2019, 10, 2094.	12.8	51
15	Immune checkpoint blockade for treating progressive multifocal leukoencephalopathy. <i>Lancet Neurology</i> , The, 2019, 18, 623-624.	10.2	1
16	Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641983657.	3.5	83
17	Immune dysbalance in childhood multiple sclerosis: a "chicken or the egg" conundrum. <i>Brain</i> , 2019, 142, 490-492.	7.6	2
18	Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis. <i>Journal of Clinical Investigation</i> , 2019, 129, 4758-4768.	8.2	81

#	ARTICLE	IF	CITATIONS
19	Abundant glutamic acid decarboxylase (GAD)â€reactive B cells in gadâ€antibodyâ€associated neurological disorders. <i>Annals of Neurology</i> , 2019, 85, 448-454.	5.3	18
20	Association of smoking but not HLA-DRB1*15:01, <i>APOE</i> or body mass index with brain atrophy in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 661-668.	3.0	12
21	Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 991-994.	3.0	38
22	Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. <i>Annals of Neurology</i> , 2018, 84, 315-328.	5.3	140
23	Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement. <i>Journal of Immunology</i> , 2017, 198, 3081-3088.	0.8	53
24	T Cellâ€Transfer Experimental Autoimmune Encephalomyelitis: Pillar of Multiple Sclerosis and Autoimmunity. <i>Journal of Immunology</i> , 2017, 198, 3381-3383.	0.8	8
25	Ocrelizumab in multiple sclerosis: markers and mechanisms. <i>Lancet Neurology</i> , The, 2017, 16, 259-261.	10.2	16
26	Patient-to-patient transmission of natalizumab-associated PML?. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1564-1565.	3.0	2
27	Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10719-10724.	7.1	666
28	Visualizing context-dependent calcium signaling in encephalitogenic T cells in vivo by two-photon microscopy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6381-E6389.	7.1	46
29	Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. <i>Nature Reviews Neurology</i> , 2017, 13, 755-763.	10.1	139
30	Cytotoxic T cells go awry in inclusion body myositis. <i>Brain</i> , 2016, 139, 1312-1314.	7.6	14
31	Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E2973-82.	7.1	157
32	Features of Human CD3+CD20+ T Cells. <i>Journal of Immunology</i> , 2016, 197, 1111-1117.	0.8	144
33	Antiglutamatergic therapy for multiple sclerosis?. <i>Lancet Neurology</i> , The, 2016, 15, 1003-1004.	10.2	5
34	Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e257.	6.0	178
35	CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis. <i>Annals of Neurology</i> , 2016, 80, 294-300.	5.3	94
36	Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 7864-7869.	7.1	145

#	ARTICLE	IF	CITATIONS
37	Guidelines on dermatomyositis excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. JDDG - Journal of the German Society of Dermatology, 2016, 14, 321-338.	0.8	43
38	Mitochondrial DNA Variation and Heteroplasmy in Monozygotic Twins Clinically Discordant for Multiple Sclerosis. Human Mutation, 2016, 37, 765-775.	2.5	41
39	The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurology, The, 2016, 15, 317-331.	10.2	160
40	The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets. Lancet Neurology, The, 2016, 15, 198-209.	10.2	156
41	Fingolimod induces neuroprotective factors in human astrocytes. Journal of Neuroinflammation, 2015, 12, 184.	7.2	70
42	Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid. Journal of Neuroinflammation, 2015, 12, 235.	7.2	86
43	Multiple sclerosis-like lesions and type I interferon signature in a patient with RVCL. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e55.	6.0	27
44	The Immunoregulator Soluble TACI Is Released by ADAM10 and Reflects B Cell Activation in Autoimmunity. Journal of Immunology, 2015, 194, 542-552.	0.8	99
45	Long-term effects of fingolimod in multiple sclerosis. Neurology, 2015, 84, 1582-1591.	1.1	173
46	Î±Î² T-cell receptors from multiple sclerosis brain lesions show MAIT cell-related features. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e107.	6.0	52
47	Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation. Brain, 2014, 137, 2703-2714.	7.6	69
48	From classic to spontaneous and humanized models of multiple sclerosis: Impact on understanding pathogenesis and drug development. Journal of Autoimmunity, 2014, 54, 33-50.	6.5	148
49	Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod. Multiple Sclerosis Journal, 2014, 20, 1714-1720.	3.0	25
50	A bird's-eye view of T cells during natalizumab therapy. Neurology, 2013, 81, 1372-1373.	1.1	3
51	Î²-Amyloid: Enemy or Remedy?. Science Translational Medicine, 2012, 4, 145fs24.	12.4	3
52	Update on sporadic inclusion body myositis. Brain, 2011, 134, 3141-3145.	7.6	16
53	Review: "Gimme five": future challenges in multiple sclerosis.ECTRIMS Lecture 2009. Multiple Sclerosis Journal, 2010, 16, 3-14.	3.0	10
54	Multiple sclerosis: Human model for EAE?. European Journal of Immunology, 2009, 39, 2036-2039.	2.9	31

#	ARTICLE	IF	CITATIONS
55	Progress in understanding inflammatory and autoimmune diseases of the central nervous system. <i>Seminars in Immunopathology</i> , 2009, 31, 437-438.	6.1	2
56	Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. <i>Nature Medicine</i> , 2008, 14, 688-693.	30.7	247
57	Neurotrophic cross-talk between the nervous and immune systems: Relevance for repair strategies in multiple sclerosis?. <i>Journal of the Neurological Sciences</i> , 2008, 265, 93-96.	0.6	42
58	Dual role of inflammation in CNS disease. <i>Neurology</i> , 2007, 68, S58-S63.	1.1	100
59	Does inflammation stimulate remyelination?. <i>Journal of Neurology</i> , 2007, 254, 147-154.	3.6	15
60	Immunologic factors in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, S16-S22.	3.0	11
61	Basic Principles of Immunotherapy for Neurologic Diseases. <i>Seminars in Neurology</i> , 2003, 23, 121-132.	1.4	20
62	The basis of immunotherapy in neurological disease. , 2002, , 1527-1546.		0
63	The ups and downs of multiple sclerosis therapeutics. <i>Annals of Neurology</i> , 2001, 49, 281-284.	5.3	61
64	Myasthenia gravis: selective enrichment of antiacetylcholine receptor antibody production in untransformed human B cell cultures. <i>European Journal of Immunology</i> , 1999, 29, 3538-3548.	2.9	3
65	Genetic control of multiple sclerosis: Increased production of lymphotoxin and tumor necrosis factor- γ by HLA-DR2+ T cells. <i>Annals of Neurology</i> , 1995, 38, 723-730.	5.3	81
66	Activation of a myelin basic protein-specific human T cell clone by antigen-presenting cells from rhesus monkeys. <i>International Immunology</i> , 1995, 7, 1489-1495.	4.0	39
67	Transplantation of Myasthenia Gravis Thymus to SCID Mice. <i>Annals of the New York Academy of Sciences</i> , 1993, 681, 66-73.	3.8	16
68	Autoimmune human T lymphocytes specific for acetylcholine receptor. <i>Nature</i> , 1984, 310, 244-246.	27.8	214